Nanopharmaceutics Completes Phase II Enrollment for Triapine Combination Therapy in Neuroendocrine Tumors
核心洞察
Nanopharmaceutics (搜索) has completed enrollment of 94 patients in a National Cancer Institute-sponsored Phase II randomized trial testing Triapine plus lutetium Lu 177 dotatate versus standard therapy alone for metastatic neuroendocrine tumors (搜索).
The study passed pre-planned interim safety review and futility assessment, with primary endpoint data awaiting maturity to evaluate overall response rates between the combination and standard therapy arms.
Phase I study results combining Triapine with lutetium Lu 177 dotatate will be presented at the 2025 ESMO Congress, marking continued advancement of this ribonucleotide reductase (搜索) inhibitor approach.
Nanopharmaceutics (搜索), Inc. has completed patient enrollment in a 94-patient Phase II randomized clinical trial evaluating the combination of Triapine plus lutetium Lu 177 dotatate versus standard therapy alone for patients with well-differentiated somatostatin receptor (搜索)-positive neuroendocrine tumors (搜索). The National Cancer Institute-sponsored study (NCT05724108) represents a significant milestone in developing enhanced treatment options for metastatic neuroendocrine tumors.
Phase II Trial Design and Objectives
The randomized Phase II trial is evaluating the overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as its primary objective, comparing combination Triapine plus lutetium Lu 177 dotatate (treatment arm 1) versus standard of care lutetium Lu 177 dotatate alone (treatment arm 2). The secondary objective focuses on evaluating progression-free survival between the two treatment arms.
The study tests whether adding Triapine improves tumor shrinkage or slows tumor growth in patients with metastatic neuroendocrine tumors (搜索) compared to standard therapy. According to the company, the Phase II trial has passed the pre-planned interim safety review and interim futility assessment and is awaiting primary endpoint maturity.
Mechanism of Action and Drug Profile
Triapine is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity. As a ribonucleotide reductase (搜索) inhibitor, also known as 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis.
Lutetium Lu 177 dotatate is a radioactive drug that binds to somatostatin receptors found on some neuroendocrine tumor cells. The compound builds up in these cells and delivers targeted radiation that may kill them, functioning as both a radioconjugate and somatostatin analog.
ESMO Congress Presentation
The company announced that Phase I study results will be presented at the European Society for Medical Oncology (ESMO) Congress, held from October 17-21, 2025 in Berlin, Germany. Dr. Aman Chauhan, Associate Professor of Medical Oncology and Leader of the Neuroendocrine Tumor Program at University of Miami Sylvester Comprehensive Cancer Center (搜索), will present the data on October 20th during the Mini oral session on NETs and endocrine tumors.
The Phase I study (NCT04234568) tested the addition of Triapine to standard radiation-based treatment with lutetium Lu 177 dotatate in patients with progressive well-differentiated gastroenteropancreatic neuroendocrine tumors (搜索).
Clinical Development Program
Both the Phase I and Phase II studies are being conducted under a Cooperative Research and Development Agreement (CRADA) between the National Cancer Institute and Nanopharmaceutics (搜索). The trials are managed by the NCI-funded Experimental Therapeutics Clinical Trials Network (ETCTN), with the Ohio State University Comprehensive Cancer Center serving as the lead institution for the Phase II study.
The Phase II trial was conducted across 14 sites throughout the United States, demonstrating the multi-institutional commitment to advancing treatment options for neuroendocrine tumor patients. The completion of enrollment represents a critical step toward generating definitive efficacy data for this combination approach.